RE:Sorry wrong Link last post :-( Oden6570.
In the article you provided there is a sub-article.
Sample page for NMIBC Market Outlook Report It is mentioned that in Japan Adstiladrin is expected to capture the largest market shares for BCG resistant patients.
From what I read on this board Adstiladrin is a repeated treatment has contraindications and has a much lower CR% at 450 days than TLT treatment.
Adstiladrin is absolutely not in the same class as TLT treatment.
Let's be clear on something Japan is a very very small market, but that is not the point, the point is that if Adstiladrin is the best treatment they can offer to BCG resistant patients, then there is an urgent need for a better alternative like TLT treatment.
The same apply to other much bigger market like US.